Pfizer experienced a remarkable first quarter, earning praise from Wall Street and CEO Albert Bourla during a companywide town hall. This came after a challenging year in which Pfizer’s shares dropped over 40%, following a significant decline in revenue from its Covid-19 products. Despite the recent positive results, Pfizer employees face uncertainty and morale issues due to strategic shifts and cost-cutting measures.
In October, Pfizer launched a multibillion-dollar cost-cutting program, which included slashing research and development spending and laying off hundreds of employees. The company aims to save $4 billion by the end of the year. Bourla acknowledged the pain of these layoffs but emphasized their necessity to regain Wall Street’s favor. “It’s very painful, but it works,” he said, noting Wall Street’s positive response.
The company’s dramatic rise and subsequent challenges have left employees uncertain about the future. While some feel optimistic following the strong first quarter, others are dissatisfied with increased workloads and the return-to-office policy. Current and former employees described higher workloads and a lack of transparency around the layoffs, which affected morale and motivation.
Pfizer has also implemented a multiyear cost-cutting program, stoking fears of further layoffs. Employees in manufacturing and supply chain divisions expressed concerns about potential job cuts. Some former employees, laid off or resigned in the past six months, criticized the company for focusing more on stock performance than on its staff.
During the recent town hall, Bourla and Chief Human Experience Officer Payal Sahni Becher discussed the layoffs but provided few details. This lack of transparency and the casual tone of the meeting frustrated many employees. The company’s return-to-office policies, which forced some remote workers to return to in-person work or face termination, further strained employee relations.
Despite these challenges, Pfizer remains committed to its strategic goals. The company aims to maximize new product performance, innovate its drug pipeline, grow its oncology business, and manage its capital effectively. Pfizer is focusing on expanding its portfolio, including the acquisition of cancer drugmaker Seagen, expected to contribute significantly to future revenue.
Bourla acknowledged the difficulties of 2023 but emphasized that Pfizer is starting 2024 with a “clean slate.” He expressed confidence in the company’s direction and reassured employees that, despite inevitable ups and downs, Pfizer is poised for growth. “The direction I’m very confident is going to be upwards,” he said, aiming to restore the pride employees felt during the peak years of 2020 to 2022.
READ MORE: